Insmed Incorporated
Clinical trials sponsored by Insmed Incorporated, explained in plain language.
-
New inhaled powder shows promise for Long-Term PAH control
Disease control OngoingThis study is testing the long-term safety and tolerability of an inhaled treprostinil powder (TPIP) in people with pulmonary arterial hypertension (PAH). About 91 participants who completed earlier TPIP studies will receive the drug for up to several years. Researchers will moni…
Phase: PHASE2, PHASE3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug brensocatib offered to bronchiectasis patients who completed key trial
Disease control APPROVED_FOR_MARKETINGThis study provides early access to brensocatib, an experimental tablet, for people with non-cystic fibrosis bronchiectasis who finished the ASPEN trial. Participants must have already taken brensocatib without serious side effects. The goal is to offer continued treatment while …
Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC